CN102603612A - 多奈哌齐盐的多晶型物及其制备和应用 - Google Patents

多奈哌齐盐的多晶型物及其制备和应用 Download PDF

Info

Publication number
CN102603612A
CN102603612A CN2012100165448A CN201210016544A CN102603612A CN 102603612 A CN102603612 A CN 102603612A CN 2012100165448 A CN2012100165448 A CN 2012100165448A CN 201210016544 A CN201210016544 A CN 201210016544A CN 102603612 A CN102603612 A CN 102603612A
Authority
CN
China
Prior art keywords
formula
compound
acid
polymorphic form
iii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2012100165448A
Other languages
English (en)
Chinese (zh)
Inventor
张和胜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HAINAN HAILING CHEMICAL PHARMACEUTICAL CO Ltd
TIANJIN HEMEI BIOTECHNOLOGY CO Ltd
Tianjin Hemay Biotechnology Co Ltd
Original Assignee
HAINAN HAILING CHEMICAL PHARMACEUTICAL CO Ltd
TIANJIN HEMEI BIOTECHNOLOGY CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HAINAN HAILING CHEMICAL PHARMACEUTICAL CO Ltd, TIANJIN HEMEI BIOTECHNOLOGY CO Ltd filed Critical HAINAN HAILING CHEMICAL PHARMACEUTICAL CO Ltd
Priority to CN2012100165448A priority Critical patent/CN102603612A/zh
Publication of CN102603612A publication Critical patent/CN102603612A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
    • C07C65/10—Salicylic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2012100165448A 2007-09-28 2008-09-24 多奈哌齐盐的多晶型物及其制备和应用 Pending CN102603612A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2012100165448A CN102603612A (zh) 2007-09-28 2008-09-24 多奈哌齐盐的多晶型物及其制备和应用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN200710061212 2007-09-28
CN200710061212.0 2007-09-28
CN200810052067.4 2008-01-15
CN200810052067 2008-01-15
CN2012100165448A CN102603612A (zh) 2007-09-28 2008-09-24 多奈哌齐盐的多晶型物及其制备和应用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2008102117315A Division CN101397270B (zh) 2007-09-28 2008-09-24 多奈哌齐盐的多晶型物及其制备和应用

Publications (1)

Publication Number Publication Date
CN102603612A true CN102603612A (zh) 2012-07-25

Family

ID=40566980

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2012100165448A Pending CN102603612A (zh) 2007-09-28 2008-09-24 多奈哌齐盐的多晶型物及其制备和应用
CN2008102117315A Active CN101397270B (zh) 2007-09-28 2008-09-24 多奈哌齐盐的多晶型物及其制备和应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2008102117315A Active CN101397270B (zh) 2007-09-28 2008-09-24 多奈哌齐盐的多晶型物及其制备和应用

Country Status (7)

Country Link
US (2) US8501779B2 (enExample)
EP (1) EP2204364B1 (enExample)
JP (1) JP5426554B2 (enExample)
CN (2) CN102603612A (enExample)
DK (1) DK2204364T3 (enExample)
ES (1) ES2415166T3 (enExample)
WO (1) WO2009049479A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100113793A1 (en) * 2006-03-20 2010-05-06 Ind-Swift Laboratories Limited Process for the Preparation of Highly Pure Donepezil
JP5563841B2 (ja) * 2010-02-05 2014-07-30 沢井製薬株式会社 薬物の不快な味をマスキングした経口医薬組成物
GB201411802D0 (en) * 2014-07-02 2014-08-13 Univ Bradford Effervescent compositions
CN104958254A (zh) * 2015-06-27 2015-10-07 万特制药(海南)有限公司 一种盐酸多奈哌齐口服溶液及其制备方法
US20220023276A1 (en) * 2018-11-26 2022-01-27 Industry-Academic Cooperation Foundation, Yonsei University Donepezil eutectic mixture and use thereof
KR102318249B1 (ko) * 2018-11-26 2021-10-27 에바바이오 주식회사 도네페질 이온성 액체 및 이의 용도
US20230054895A1 (en) * 2020-01-10 2023-02-23 President And Fellows Of Harvard College Methods for inducing biostasis in a cell, tissue or organ

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
RU2190603C2 (ru) * 1996-06-07 2002-10-10 Эйсай Ко., Лтд. Полиморфные модификации донепезила гидрохлорида, способы их получения и способ лечения заболевания, сопровождающегося активностью ацетилхолинэстеразы
JPH1053576A (ja) * 1996-06-07 1998-02-24 Eisai Co Ltd 塩酸ドネペジルの多形結晶およびその製造法
US7439365B2 (en) 2003-11-17 2008-10-21 Usv, Ltd. Pharmaceutical salt of (1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl] methyl piperidine (Donepezil)
US20050288330A1 (en) * 2004-06-29 2005-12-29 Avinash Naidu Process for producing a polymorphic form of (1-Benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl] methyl piperidine hydrochloride (donepezil hydrochloride)
HUP0401850A3 (en) * 2004-09-15 2008-03-28 Egis Gyogyszergyar Nyilvanosan Donepezil salts for producing pharmaceutical composition
DE102004046497A1 (de) * 2004-09-23 2006-04-06 Helm Ag Donepezil-Salze
CA2581926A1 (en) * 2004-09-29 2006-04-06 Chemagis Ltd. Use of purified donepezil maleate for preparing pharmaceutically pure amorphous donepezil hydrochloride
CN1759836A (zh) * 2004-10-12 2006-04-19 天津和美生物技术有限公司 多奈哌齐及其衍生物的舌下含片
US20090171094A1 (en) * 2005-07-15 2009-07-02 Kazuhide Ashizawa 1-benzyl-4-[(5, 6-dimethoxy- 1- indanon)- 2- yl]-methyl piperidine p-toluenesulfonate or crystal thereof
HU227474B1 (en) * 2005-12-20 2011-07-28 Richter Gedeon Nyrt Process for industrial scale production of high purity donepezil hydrochloride polymorph i.

Also Published As

Publication number Publication date
JP5426554B2 (ja) 2014-02-26
EP2204364B1 (en) 2013-03-20
CN101397270A (zh) 2009-04-01
WO2009049479A1 (en) 2009-04-23
US20100311793A1 (en) 2010-12-09
CN101397270B (zh) 2012-03-28
US8501779B2 (en) 2013-08-06
US20130296283A1 (en) 2013-11-07
EP2204364A1 (en) 2010-07-07
ES2415166T3 (es) 2013-07-24
DK2204364T3 (da) 2013-06-03
JP2010540470A (ja) 2010-12-24
EP2204364A4 (en) 2011-08-10
HK1146047A1 (en) 2011-05-13

Similar Documents

Publication Publication Date Title
Shanbhag et al. Ester and amide prodrugs of ibuprofen and naproxen: synthesis, anti-inflammatory activity, and gastrointestinal toxicity
CN102603612A (zh) 多奈哌齐盐的多晶型物及其制备和应用
US4927855A (en) Levorotatory isomer of benzhydrylsulfinyl derivatives
AU731282B2 (en) Polymorphs of donepezil hydrochloride and process for production
US5985864A (en) Polymorphs of donepezil hydrochloride and process for production
JPS5912650B2 (ja) フエニル脂肪族飽和カルボン酸の塩類の製造法
JP2005015486A (ja) 塩酸ドネペジルの多形結晶およびその製造法
EP0508586A1 (en) Substituted indenyl compounds
EP0485172A2 (en) Esters and amides of substituted indenyl acetic acids
US20020107248A1 (en) Method for treating patients with neoplasia by administering substituted sulfonyl indenyl acetic and propionic acids and esters thereof
US6861555B2 (en) Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith
US20150239890A1 (en) Crystal of n-[2-(amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide
EP1259474B1 (en) Calcium dicarboxylate ethers, methods of making same
CN118754865A (zh) 黄芩素衍生物及其制备方法和作为胰脂肪酶抑制剂的应用
US9586925B2 (en) 1-(dimethylamino)ethyl-substituted 6H-benzo[C]chromen-6-ones against senile dementia
US4229446A (en) Aluminum acetylsalicylate glutaminate
NO760116L (enExample)
HK1146047B (en) Polymorphs of donepezil salts, preparation methods and uses thereof
KR20200110308A (ko) 트리메부틴 말레산염의 다형체 및 이의 사용방법
HU188170B (en) Process for producing 3-square bracket-2-bracket-tetra-or hexahydro.4-pyridyl-bracket closed-ethyl-s uare bracket closed-indola derivatives
JP2024511990A (ja) 障害の処置用の化合物ならびにその塩および多形体
ES2380799T3 (es) Sal de ácido fumárico y 3-(2-dimetilamino)metil- (cicloex-1-il))-fenol y sus formas cristalinas
KR20250081156A (ko) L-세린 염산염의 제조 방법 및 이의 용도
JPS6218555B2 (enExample)
JPH03291266A (ja) ピロールアルデヒド誘導体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20120725

C20 Patent right or utility model deemed to be abandoned or is abandoned